Building the Future of
Israeli Biotech


Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israeli-based biotech companies.

Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs. We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance. The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.


“We invest in Israeli and Israeli related biotechnology and pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential.”

Our key asset is a unique team of nearly 30 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.

We provide our portfolio companies with the necessary resources for long-term sustainable growth. We provide them with access to network, executive talent, strategic, operational, and business development resources.

This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.



Venture Advisors



Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial

MISGAV, Israel, June 24, 2024 /PRNewswire/ — Biond Biologics Ltd. (“Biond” or the “Company”), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy …

CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) …


Israel Biotech Fund
HaOgen B, 4 Oppenheimer St., 
Rehovot 7670104, Israel

Parking (payable) available at the building.

We would be happy to hear from you
and learn more about your company and
technology. Please feel free to contact us at: [email protected]